The US Pharmaceutical Research and Manufacturers of America (PhRMA) has elected Anglo-Swedish drug major AstraZeneca's chief executive, David Brennan, a US citizen, as board chairman replacing Richard Clark, the CEO and president of US drug major Merck & Co. The handover was effected at the PhRMA's meeting in San Antonio, Texas, where the new chairman outlined his vision for the industry.
Mr Brennan began by noting that "we are in the midst of a deepening global economic recession. Since the onset of this downturn in the United States alone, over 4.4 million people have lost their jobs and, in many instances, they've also lost their health insurance. It's not hyperbole to say that before this recession is over millions more will join the 47 million other Americans who do not have health insurance."
"Unsustainable" health costs by 2016
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze